Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors

S.K. Moerk; M. Donia; J.V. Kringelum; T. Bogenrieder; B. Rønø; A.B. Sorensen; A. Draghi; K F Bol; N.V. Petersen; M. Kadivar; S S Hernandez; S. Reker Hadrup; L.V. Andreasen; D. Christensen; P.L. Andersen; I.M. Svane

doi:10.1093/annonc/mdz451.019

Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors

S.K. Moerk, M. Donia, J.V. Kringelum, T. Bogenrieder, B. Rønø, A.B. Sorensen, A. Draghi, K F Bol, N.V. Petersen, M. Kadivar, S S Hernandez, S. Reker Hadrup, L.V. Andreasen, D. Christensen, P.L. Andersen, I.M. Svane

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	111P
Journal	Annals of Oncology
Volume	30
Issue number	Supplement_11
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdz451.019
Publication status	Published - 2019
Event	ESMO Immuno-Oncology Congress 2019 - Geneva, Switzerland Duration: 11 Dec 2019 → 14 Dec 2019

Conference

Conference	ESMO Immuno-Oncology Congress 2019
Country/Territory	Switzerland
City	Geneva
Period	11/12/2019 → 14/12/2019

Access to Document

10.1093/annonc/mdz451.019

OpenUrl availability

Full text

Cite this

Moerk, S. K., Donia, M., Kringelum, J. V., Bogenrieder, T., Rønø, B., Sorensen, A. B., Draghi, A., Bol, K. F., Petersen, N. V., Kadivar, M., Hernandez, S. S., Hadrup, S. R., Andreasen, L. V., Christensen, D., Andersen, P. L., & Svane, I. M. (2019). Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors. Annals of Oncology, 30(Supplement_11), Article 111P. https://doi.org/10.1093/annonc/mdz451.019

@article{e71c1cc93dc94333b74bf8a3fd156a01,

title = "Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors",

author = "S.K. Moerk and M. Donia and J.V. Kringelum and T. Bogenrieder and B. R{\o}n{\o} and A.B. Sorensen and A. Draghi and Bol, {K F} and N.V. Petersen and M. Kadivar and Hernandez, {S S} and Hadrup, {S. Reker} and L.V. Andreasen and D. Christensen and P.L. Andersen and I.M. Svane",

year = "2019",

doi = "10.1093/annonc/mdz451.019",

language = "English",

volume = "30",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Supplement_11",

note = " ESMO Immuno-Oncology Congress 2019 ; Conference date: 11-12-2019 Through 14-12-2019",

}

Moerk, SK, Donia, M, Kringelum, JV, Bogenrieder, T, Rønø, B, Sorensen, AB, Draghi, A, Bol, KF, Petersen, NV, Kadivar, M, Hernandez, SS, Hadrup, SR, Andreasen, LV, Christensen, D, Andersen, PL & Svane, IM 2019, 'Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors', Annals of Oncology, vol. 30, no. Supplement_11, 111P. https://doi.org/10.1093/annonc/mdz451.019

Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors. / Moerk, S.K.; Donia, M.; Kringelum, J.V. et al.
In: Annals of Oncology, Vol. 30, No. Supplement_11, 111P, 2019.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors

AU - Moerk, S.K.

AU - Donia, M.

AU - Kringelum, J.V.

AU - Bogenrieder, T.

AU - Rønø, B.

AU - Sorensen, A.B.

AU - Draghi, A.

AU - Bol, K F

AU - Petersen, N.V.

AU - Kadivar, M.

AU - Hernandez, S S

AU - Hadrup, S. Reker

AU - Andreasen, L.V.

AU - Christensen, D.

AU - Andersen, P.L.

AU - Svane, I.M.

PY - 2019

Y1 - 2019

U2 - 10.1093/annonc/mdz451.019

DO - 10.1093/annonc/mdz451.019

M3 - Conference abstract in journal

SN - 0923-7534

VL - 30

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement_11

M1 - 111P

T2 - ESMO Immuno-Oncology Congress 2019

Y2 - 11 December 2019 through 14 December 2019

ER -